{"id":668293,"date":"2023-09-18T17:48:02","date_gmt":"2023-09-18T17:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=668293"},"modified":"2023-09-18T17:48:02","modified_gmt":"2023-09-18T17:48:02","slug":"rett-syndrome-pipeline-drugs-key-companies-insight-report-2023-companies-acadia-pharmaceuticalsneuren-pharmaceutical-gw-research","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/rett-syndrome-pipeline-drugs-key-companies-insight-report-2023-companies-acadia-pharmaceuticalsneuren-pharmaceutical-gw-research_668293.html","title":{"rendered":"Rett Syndrome Pipeline Drugs & Key Companies Insight Report 2023 | Companies – Acadia Pharmaceuticals\/Neuren Pharmaceutical, GW Research"},"content":{"rendered":"
\n
\"Rett<\/a><\/div>\n
\n
Rett Syndrome Pipeline Insights Report 2023<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cRett Syndrome – Pipeline Insight, 2023,\u201d report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Rett Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/div>\n

DelveInsight’s “Rett Syndrome Pipeline Insight 2023<\/a>”<\/strong> report provides comprehensive insights about key companies and pipeline drugs in the Rett Syndrome pipeline landscapes. <\/p>\n

The report comprises Rett Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Rett Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Rett Syndrome pipeline products.     <\/p>\n

Rett Syndrome Overview<\/strong><\/p>\n

Rett syndrome is a unique neurodevelopmental disorder that is first noticed in infancy and primarily affects girls but can be rarely seen in boys. It is caused by mutations on the X-chromosome on a gene called MECP2. There are more than 200 different mutations found in the MECP2 gene. Most of these mutations are found in eight different “hot spots.” Rett syndrome is mostly misdiagnosed as autism, cerebral palsy, or global developmental delay. It is found in all ethnic and racial groups.<\/p>\n

Rett syndrome is not a degenerative disorder but causes problems in brain function that are responsible for cognitive, sensory, emotional, motor, and autonomic functions. These can include learning, speech, sensory sensations, mood, movement, breathing, cardiac function, and even chewing, swallowing, and digestion.<\/p>\n

Some of the key takeaways from the Rett Syndrome Pipeline Report<\/a>:<\/strong><\/p>\n